All‐trans retinoic acid and arsenic combination therapy benefits low‐to‐intermediate‐risk patients with newly diagnosed acute promyelocytic leukaemia: a long‐term follow‐up based on multivariate analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 277-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-02 ,pp. : 1-8

Karger

Access to resources Recommend Favorite

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐trans retinoic acid and arsenic trioxide

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 471-477

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 101-108

Karger

Access to resources Recommend Favorite

Long‐term follow‐up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1013-1020

John Wiley & Sons Inc

Access to resources Recommend Favorite